Partial
Partially Aligned
Patient Risk:
Low
Summary
The claims concern patent expiration and regulatory exclusivity information not present in FDA labeling; the claims appear not aligned with the label content.
Category Scores
Accurate Statements
Unsupported Statements
The composition & formulation patent USPTO 7,584,234 (apixaban) expires March 12, 2027.
Patent information is not part of FDA labeling.
This patent covers the active‑ingredient formulation and its most common dosage strengths (2 mg and 5 mg tablets).
Patent information is not part of FDA labeling.
The manufacturing process patent USPTO 7,878,487 (process for preparing apixaban) expires July 10, 2028.
Patent information is not part of FDA labeling.
This patent covers a key synthesis route that many generic producers use.
Patent information is not part of FDA labeling.
US Patent 7,976,903 (packaging & labeling) expires July 10, 2028.
Patent information is not part of FDA labeling.
This patent relates to the specific tablet coating and labeling method used by Eliquis.
Patent information is not part of FDA labeling.
Patent expiration means a manufacturer can, in theory, file a generic (biosimilar‑free) application after the final relevant patent expires.
Patent information is not part of FDA labeling.
If a patent holder seeks an extension (e.g., for “product‑like” claims or “shelf‑life” claims), the effective expiration could be later.
Patent information is not part of FDA labeling.
FDA must still approve a generic version.
Regulatory approval pathways for generics are not discussed in FDA labeling.
Teva’s generic apixaban (apixaban-1) was cleared in 2023, but it was still under the protection of a product‑like patent that expired in 2026–2027.
Generic development/patent status is not specified in the FDA label.
The main formulation patent is set to expire on March 12, 2027.
Patent expiry dates are not disclosed in FDA labeling.
Process‑ and packaging‑related patents will expire on July 10, 2028.
Patent expiry details are not part of FDA labeling.
If you’re planning a generic launch or a competitive pricing strategy, keep an eye on any post‑expiration litigation or secondary patent renewals, as those can delay the availability of a truly “off‑patent” Eliquis.
Labeling does not provide strategic guidance on post‑expiration litigation or patent renewals.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The content evaluated concerns patent law and regulatory exclusivity, not patient safety or adverse event data.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Patent-related content is not part of FDA labeling and misaligns with on-label content.
Suggested Improvement
Limit statements to FDA-approved labeling content (indication, dosing, safety, administration, etc.) and avoid patent-status or exclusivity discussions unless clearly distinguished as regulatory/market context outside labeling.